Genmab — Marts 2017
-
Ser stadig en risiko for, at isatuximab kan komme ind på markedet via kombinationen med Pom/Dex - de bliver formentlig de første der præsenterer fase III data, hvilket jeg egentlig synes er lidt ærgeligt. Specielt hvis Dara/Pom/Dex godkendelsen glipper hos FDA ! Det er helt sikkert vejen ind på markedet for ImmunoGen/Sanofi og den kunne Janssen godt have lukket
-
Tror nu heller ikke godkendelsen fejler, men det er trods alt kun fase II data - og EMA gider åbenbart ikke kigge på evt. godkendelse. Desuden blev det af KOL i en af de links der er langt herinde nævnt, at der var nogle bivirkninger med Dara/Pom/Dex kombien - tror man gik ned i Pom dosis for at undgå det, men igen en ting der måske kan kræve yderligere undersøgelser.
-
Spørg eventuelt i Aktiesnakken? Ikke mange her har aktien.
-
d. 22
-
Et eksempel fra Darza-facebookgruppen: "HAVE A QUESTION for all of you re which treatment meds u are on in ADDITION to Darza, as my Dr wanted to add Pom or Velcade to the Darzalex Dex mix. Pom caused me to be Neutropenic, so we went with Velcade, but I was surprised when she and my chemo pharmacist told me the Velcade shots would be 2x per week! One on Darza infusion day, and the 2nd shot, 2days later."
-
Ditto her.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind